What was a significant corporate event for Omrix Biopharmaceuticals?

Omrix Biopharmaceuticals was acquired by Johnson & Johnson in November 2008, leading to its integration into Johnson & Johnson's Medical Device and Diagnostics Sector, reporting through Ethicon Inc.

When did Omrix Biopharmaceuticals go public?

Omrix Biopharmaceuticals completed an Initial Public Offering (IPO) on NASDAQ in January 2005.

Which investors participated in Omrix Biopharmaceuticals' March 2005 funding round?

In March 2005, Omrix Biopharmaceuticals received investment from Catalyst and Hercules Capital, Inc.

What is the primary focus of Omrix Biopharmaceuticals' product development?

Omrix Biopharmaceuticals focuses on developing and manufacturing products derived from human plasma, including biosurgical hemostatic products and passive immunotherapy products.

What happened to Omrix Biopharmaceuticals' public listing?

Omrix Biopharmaceuticals was delisted from NASDAQ in January 2009, following its acquisition by Johnson & Johnson.

Omrix Biopharmaceuticals

Human Plasma Derived Products

Health Tech & Life Sciences

Acquired (Inactive) by Johnson & Johnson on Nov 2008 - closed due to acquisition

Company Overview

Snapshot

Founded in June 1995, Omrix Biopharmaceuticals operated with 201–500 employees. The company raised $4.84M across two funding rounds with two investors. A significant milestone was its acquisition by Johnson & Johnson in November 2008.

Business overview

Omrix Biopharmaceuticals specializes in the development and manufacture of products derived from human plasma, utilizing patented technology for global distribution. The company's product portfolio includes biosurgical hemostatic products designed for bleeding control during surgery, as well as passive immunotherapy products for patients with immune deficiencies. Operating within the Health Tech & Life Sciences sector, Omrix serves the medical products industry, focusing on healthcare providers and patients.

Strategic signal

Omrix Biopharmaceuticals was acquired by Johnson & Johnson in November 2008. This acquisition integrated Omrix's specialized human plasma-derived products and biosurgical solutions into a major global healthcare conglomerate, signaling a strategic move by Johnson & Johnson to enhance its Medical Device and Diagnostics Sector, specifically through Ethicon Inc. The event underscored the value of Omrix's patented technology and product lines in the biopharmaceutical market.

Company Intelligence Q&A

What was a significant corporate event for Omrix Biopharmaceuticals?: Omrix Biopharmaceuticals was acquired by Johnson & Johnson in November 2008, leading to its integration into Johnson & Johnson's Medical Device and Diagnostics Sector, reporting through Ethicon Inc.
When did Omrix Biopharmaceuticals go public?: Omrix Biopharmaceuticals completed an Initial Public Offering (IPO) on NASDAQ in January 2005.
Which investors participated in Omrix Biopharmaceuticals' March 2005 funding round?: In March 2005, Omrix Biopharmaceuticals received investment from Catalyst and Hercules Capital, Inc.
What is the primary focus of Omrix Biopharmaceuticals' product development?: Omrix Biopharmaceuticals focuses on developing and manufacturing products derived from human plasma, including biosurgical hemostatic products and passive immunotherapy products.
What happened to Omrix Biopharmaceuticals' public listing?: Omrix Biopharmaceuticals was delisted from NASDAQ in January 2009, following its acquisition by Johnson & Johnson.

After more than a decade of building and operating Finder as a resource for Israel’s technology ecosystem, Startup Nation Central concluded its operation of Finder on August 31, 2026.

It is important to us that the data and knowledge built through Finder remain available to serve the ecosystem. We are working to enable access to Israeli technology ecosystem data beyond SNC’s operation of Finder.

Registered Finder users will receive further updates by email. Confirmed updates will also be published on this page.

If you have any questions or would like to get in touch regarding Finder, please contact us at [email protected].

Thank you to the users, companies, and partners who have been part of Finder’s journey.

Name	Omrix Biopharmaceuticals
One-liner	Human Plasma Derived Products
Type	Startup
Primary sector	Health Tech & Life Sciences
Founded	1995
Employees	201-500
Employees (exact)	300
HQ / location	Ness Ziona, Einstein St 14, Nes Ziyyona, Israel, Center District
Product stage	Released
LinkedIn	https://www.linkedin.com/company/52855
Crunchbase	omrix-biopharmaceuticals
IL Registrar	512166059

Sectors	Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics
Core technology	Biologicals, Cells
Target customers	Healthcare & Life Sciences, Healthcare, Patients, Providers, Medical Devices Industry, Medical Products
Business models	B2B
Tags	surgery, immunology, medical-products, biotechnology, pharmaceuticals, biopharmaceutical

Date	Type	Amount
Nov 2008	exit	$458M
Jan 2009	exit	Undisclosed
Jan 2005	exit	Undisclosed